Welcome to our dedicated page for Deep Isolation Nuclear SEC filings (Ticker: DBHL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Deep Isolation Nuclear's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Deep Isolation Nuclear's regulatory disclosures and financial reporting.
Deep Isolation Nuclear, Inc. is registering the resale by existing holders of up to 58,506,213 shares of common stock. These shares include stock issued in a July 2025 private placement, merger consideration, legacy Aspen-1 shares and shares underlying placement agent warrants.
The company develops proprietary deep borehole disposal technology and a universal canister system to address high-level nuclear waste, and also provides environmental consulting through subsidiary Freestone. It is early stage and unprofitable: for 2025 it generated 6,136 (in thousands) of revenue and a net loss of 5,336 (in thousands), with an accumulated deficit of 32,503 (in thousands).
Common stock is not yet quoted; until a public market develops, selling stockholders may sell at a fixed $3.00 per share, implying a hypothetical offering value of $175,518,639. The company receives no proceeds from resales, but could receive up to $2,489,206.67 if placement agent warrants are exercised for cash, for general corporate purposes. The business depends on successful, multi‑year demonstration of its technology and on future regulatory approvals and customer implementation contracts, none of which are assured.